Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders
…, CL Szumlanski, RM Weinshilboum - Pharmacogenetics …, 1996 - journals.lww.com
… 893 randomly selected subjects showed that the frequency of the low activity allele was
0.46 (Spielman & Weinshilboum, 198l). Low COMT activity is also associated with enzyme …
0.46 (Spielman & Weinshilboum, 198l). Low COMT activity is also associated with enzyme …
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity
RM Weinshilboum, SL Sladek - American journal of human …, 1980 - ncbi.nlm.nih.gov
… WEINSHILBOUM RM: Human erythrocyte catechol-O-methyltransferase: correlation with
lung and kidney activity. Life Sci 22:625-630, 1978 25. REILLY DK, RIVERA-CALIMLIM L: Red …
lung and kidney activity. Life Sci 22:625-630, 1978 25. REILLY DK, RIVERA-CALIMLIM L: Red …
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
…, J Hayden, S Lemler, RM Weinshilboum… - Journal of the …, 2005 - academic.oup.com
Background: The efficacy of tamoxifen therapy for the treatment of breast cancer varies widely
among individuals. Plasma concentrations of the active tamoxifen metabolite endoxifen …
among individuals. Plasma concentrations of the active tamoxifen metabolite endoxifen …
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
…, JS Lilleyman, J Van Loon, RM Weinshilboum - The Lancet, 1990 - Elsevier
6-mercaptopurine (6-MP) can be inactivated by S-methylation, which is catalysed by
thiopurine methyltransferase (TPMT). An alternative metabolic route leads to the formation of …
thiopurine methyltransferase (TPMT). An alternative metabolic route leads to the formation of …
Metabolomics: a global biochemical approach to drug response and disease
…, BS Kristal, RM Weinshilboum - Annu. Rev. Pharmacol …, 2008 - annualreviews.org
Metabolomics is the study of metabolism at the global level. This rapidly developing new
discipline has important potential implications for pharmacologic science. The concept that …
discipline has important potential implications for pharmacologic science. The concept that …
[HTML][HTML] Genomics and drug response
…, HL McLeod, RM Weinshilboum - New England Journal of …, 2011 - Mass Medical Soc
This article reviews recent pharmacogenetic and pharmacogenomic advances and
discusses how such advances are reflected in the labeling of drugs.
discusses how such advances are reflected in the labeling of drugs.
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism
…, JA Van Loon, RM Weinshilboum - Clinical Pharmacology …, 1989 - Wiley Online Library
Azathioprine therapy can cause acute myelosuppression. Toxicity is in part caused by the
incorporation of azathioprine‐derived 6‐thioguanine nucleotides (6‐TGN) into …
incorporation of azathioprine‐derived 6‐thioguanine nucleotides (6‐TGN) into …
Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase
RM Weinshilboum, DM Otterness… - Annual review of …, 1999 - annualreviews.org
▪ Abstract Methyl conjugation is an important pathway in the biotransformation of many
exogenous and endogenous compounds. Pharmacogenetic studies of methyltransferase …
exogenous and endogenous compounds. Pharmacogenetic studies of methyltransferase …
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
…, FJ Couch, WL Lingle, RM Weinshilboum… - Breast cancer research …, 2007 - Springer
Background Tamoxifen is biotransformed to the potent anti-estrogen, endoxifen, by the
cytochrome P450 (CYP) 2D6 enzyme. CYP2D6 genetic variation and inhibitors of the enzyme …
cytochrome P450 (CYP) 2D6 enzyme. CYP2D6 genetic variation and inhibitors of the enzyme …
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
Context The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone
receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and …
receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and …